Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion type Assertion NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_head.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion description "[Thus, this study strongly suggests that pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines from autologous tumors for immunotherapy and induce immune responses against broader tumor antigens that may protect against tumor recurrence and development of unrelated tumors in vaccinated myeloma patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_provenance.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion evidence source_evidence_literature NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_provenance.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion SIO_000772 19654406 NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_provenance.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion wasDerivedFrom befree-20150227 NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_provenance.
- NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_assertion wasGeneratedBy ECO_0000203 NP757313.RAQy7co7PFFgptRYiB0ayM-qy6RsZZ_DKd7bkJCjn_VHA130_provenance.